Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial

References

• Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1–13. doi: 10.1056/NEJMra1413485.
   PubMed Web of Science ®Google Scholar
• Li SS, Hsu YT, Chang C, et al. Incidence and treatment outcome of aplastic anemia in Taiwan-real-world data from single-institute experience and a nationwide population-based database. Ann Hematol. 2019;98(1):29–39. doi: 10.1007/s00277-018-3486-3.
   PubMed Web of Science ®Google Scholar
• Vaht K, Göransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica. 2017;102(10):1683–1690. doi: 10.3324/haematol.2017.169862.
   PubMed Web of Science ®Google Scholar
• Norasetthada L, Wongkhantee S, Chaipokam J, et al. Adult aplastic anemia in Thailand: incidence and treatment outcome from a prospective nationwide population-based study. Ann Hematol. 2021;100(10):2443–2452. doi: 10.1007/s00277-021-04566-0.
   PubMed Web of Science ®Google Scholar
• Zhang XT, Wang X, Cao J, et al. Treatment outcome of 301 aplastic anemia patients in China: a 10-year follow-up and real-world data from single institute experience. Hematology. 2021;26(1):1025–1030. doi: 10.1080/16078454.2021.2009646.
   PubMed Web of Science ®Google Scholar
• Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207. doi: 10.1111/bjh.13853.
   PubMed Web of Science ®Google Scholar
• Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) severe aplastic anaemia working party. Blood. 1999;93(7):2191–2195. doi: 10.1182/blood.V93.7.2191.
   PubMed Web of Science ®Google Scholar
• Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–1550. doi: 10.1056/NEJMoa1613878.
   PubMed Web of Science ®Google Scholar
• Ecsedi M, Lengline É, Knol-Bout C, et al. Use of eltrombopag in aplastic anemia in Europe. Ann Hematol. 2019;98(6):1341–1350. doi: 10.1007/s00277-019-03652-8.
   PubMed Web of Science ®Google Scholar
• Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Blood Adv. 2018;2(21):3054–3062. doi: 10.1182/bloodadvances.2018020248.
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Levati G, Cassin R, et al. Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation. Drugs. 2019;79(12):1305–1319. doi: 10.1007/s40265-019-01159-0.
   PubMed Web of Science ®Google Scholar
• Fan X, Desmond R, Winkler T, et al. Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias. Blood Adv. 2020;4(8):1700–1710. doi: 10.1182/bloodadvances.2020001657.
   PubMed Web of Science ®Google Scholar
• Shirley M. Avatrombopag: first global approval. Drugs. 2018;78(11):1163–1168. doi: 10.1007/s40265-018-0949-8.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Reviews. 2022;53:100909. doi: 10.1016/j.blre.2021.100909.
   PubMed Web of Science ®Google Scholar
• Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis. Exp Hematol. 2008;36(10):1337–1342. doi: 10.1016/j.exphem.2008.04.020.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11):4607–4616. doi: 10.1182/blood-2006-10-019315.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Smolensky Koganov E, Forde EE, et al. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018;16(12):2515–2519. doi: 10.1111/jth.14295.
   PubMed Web of Science ®Google Scholar
• Wojciechowski P, Wilson K, Nazir J, et al. Efficacy and safety of avatrombopag in patients with chronic immune thrombocytopenia: a systematic literature review and network meta-analysis. Adv Ther. 2021;38(6):3113–3128. doi: 10.1007/s12325-021-01752-4.
   PubMed Web of Science ®Google Scholar
• Virk ZM, Kuter DJ, Al-Samkari H. An evaluation of avatrombopag for the treatment of thrombocytopenia. Expert Opin Pharmacother. 2021;22(3):273–280. doi: 10.1080/14656566.2020.1841748.
   PubMed Web of Science ®Google Scholar
• Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med. 2019;10:313–321. doi: 10.2147/JBM.S191790.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735. doi: 10.1177/2040620719841735.
   Web of Science ®Google Scholar
• Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479–490. doi: 10.1111/bjh.15573.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–3894. doi: 10.1182/blood-2013-07-514398.
   PubMed Web of Science ®Google Scholar
• Długosz-Danecka M, Zdziarska J, Jurczak W. Avatrombopag for the treatment of immune thrombocytopenia. Expert Rev Clin Immunol. 2019;15(4):327–339. doi: 10.1080/1744666X.2019.1587294.
   PubMed Web of Science ®Google Scholar
• Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131. doi: 10.1002/pbc.21039.
   PubMed Web of Science ®Google Scholar
• Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–2620. doi: 10.1002/art.38690.
   PubMed Web of Science ®Google Scholar
• Health UDo, Services H. Common terminology criteria for adverse events. Version 5.0. Published 2017 Nov 27. 2020.
   Google Scholar
• Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–19. doi: 10.1056/NEJMoa1200931.
   PubMed Web of Science ®Google Scholar
• Xu H, Cai R. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Expert Rev Clin Pharmacol. 2019;12(9):859–865. doi: 10.1080/17512433.2019.1649137.
   PubMed Web of Science ®Google Scholar
• Scharf RE. Thrombocytopenia and hemostatic changes in acute and chronic liver disease: pathophysiology, clinical and laboratory features, and management. JCM. 2021;10(7):1530. doi: 10.3390/jcm10071530.
   Google Scholar
• Terrault N, Chen YC, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):705–718. doi: 10.1053/j.gastro.2018.05.025.
   PubMed Web of Science ®Google Scholar
• Nilles KM, Flamm SL. Thrombocytopenia in chronic liver disease: new management strategies. Clin Liver Dis. 2020;24(3):437–451. doi: 10.1016/j.cld.2020.04.009.
   PubMed Web of Science ®Google Scholar
• Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs. 2021;81(11):1285–1305. doi: 10.1007/s40265-021-01553-7.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112–1123. doi: 10.3324/haematol.2018.212845.
   PubMed Web of Science ®Google Scholar
• Khellaf M, Viallard JF, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98(6):881–887. doi: 10.3324/haematol.2012.074633.
   PubMed Web of Science ®Google Scholar
• González-Porras JR, Godeau B, Carpenedo M. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719837906. doi: 10.1177/2040620719837906.
   Web of Science ®Google Scholar
• Kuter DJ, Tarantino MD, Lawrence T. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. Blood Reviews. 2021;49:100811. doi: 10.1016/j.blre.2021.100811.
   PubMed Web of Science ®Google Scholar
• Birocchi S, Podda GM, Manzoni M, et al. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review. Platelets. 2021;32(2):216–226. doi: 10.1080/09537104.2020.1745168.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Nagalla S. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets. 2022;33(2):257–264. doi: 10.1080/09537104.2021.1881952.
   PubMed Web of Science ®Google Scholar
• Agarwal N, Mangla A. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review. Ther Adv Hematol. 2021;12:20406207211001139. doi: 10.1177/20406207211001139.
   Web of Science ®Google Scholar
• Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82(4):247–254. doi: 10.1111/j.1600-0609.2008.01198.x.
   PubMed Web of Science ®Google Scholar
• Markham A. Avatrombopag: a review in thrombocytopenia. Drugs. 2021;81(16):1905–1913. doi: 10.1007/s40265-021-01613-y.
   PubMed Web of Science ®Google Scholar
• Syed YY. Hetrombopag: first approval. Drugs. 2021;81(13):1581–1585. doi: 10.1007/s40265-021-01575-1.
   PubMed Web of Science ®Google Scholar
• Young DJ, Fan X, Groarke EM, et al. Long-term eltrombopag for bone marrow failure depletes iron. American J Hematol. 2022;97(6):791–801. doi: 10.1002/ajh.26543.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang WR, Wu ZJ, et al. Delayed hematologic response to immunosuppressive therapy in severe aplastic anemia. Zhonghua Xue Ye Xue Za Zhi. 2016;37(12):1038–1043.
   PubMedGoogle Scholar
• Patel BA, Groarke EM, Lotter J, et al. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Blood. 2022;139(1):34–43. doi: 10.1182/blood.2021012130.
   PubMed Web of Science ®Google Scholar
• Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The german aplastic anemia study group. N Engl J Med. 1991;324(19):1297–1304. doi: 10.1056/NEJM199105093241901.
   PubMed Web of Science ®Google Scholar
• Lee SE, Yahng SA, Cho BS, et al. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia. Acta Haematol. 2013;129(2):72–77. doi: 10.1159/000342772.
   PubMed Web of Science ®Google Scholar
• Zaimoku Y, Patel BA, Shalhoub R, et al. Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag. haematol. 2021;107(1):126–133. doi: 10.3324/haematol.2021.278413.
   Web of Science ®Google Scholar
• Hitchcock IS, Kaushansky K. Thrombopoietin from beginning to end. Br J Haematol. 2014;165(2):259–268. doi: 10.1111/bjh.12772.
   PubMed Web of Science ®Google Scholar
• Abe M, Suzuki K, Sakata C, et al. Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist. Eur J Pharmacol. 2011;650(1):58–63. doi: 10.1016/j.ejphar.2010.09.072.
   PubMed Web of Science ®Google Scholar
• EHA 2021. Virtual congress abstract book. HemaSphere. 2021;5(S2):548.
   Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247. doi: 10.1056/NEJMoa073275.
   PubMed Web of Science ®Google Scholar
• Mishra K, Jandial A, Lad D, et al. Cost and complications are limitations in resource-constrained settings for equine anti-thymocyte globulin. Eur J Haematol. 2018;101(3):421. doi: 10.1111/ejh.13125.
   PubMed Web of Science ®Google Scholar
• Saab S, Brown RS.Jr. Management of thrombocytopenia in patients with chronic liver disease. Dig Dis Sci. 2019;64(10):2757–2768. doi: 10.1007/s10620-019-05615-5.
   PubMed Web of Science ®Google Scholar